Drug intelligence / Profile preview

VE416

Development stage: Discontinued
Lead developer: Vedanta Biosciences
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

VE416 is an investigational, orally administered live biotherapeutic product (LBP) developed by Vedanta Biosciences for the treatment of food allergies, particularly peanut allergy. [27, 29, 30] It is comprised of a defined consortium of commensal bacterial strains produced from pure, clonal cell banks, ensuring a uniform and pathogen-free composition. [24, 29] The drug is designed to modulate the gut microbiome to induce immune tolerance to food allergens. [22] In clinical trials, VE416 has been studied as a monotherapy and in combination with peanut oral immunotherapy (PNOIT). [22] Preclinical studies in mice demonstrated that VE416 could induce protective immunoregulatory responses and reduce allergic symptoms. [27]

Beyond the preview

Go deeper on VE416.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VE416.

Explore the full profile